AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune ...

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.

In several short films directed by Reed Morano, the “What science can do” campaign features stories from a cancer patient and an asthma patient.

The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...

AstraZeneca PLC AZN shares rallied 1.33% to £117.20 Thursday, on what proved to be an all-around great trading session for ...

Immunai already has strategic agreements with 30 pharmaceuticals companies, most of them involving much smaller financial ...

In June, at the American Society of Clinical Oncology (ASCO) conference in Chicago, when AstraZeneca discussed results from a ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp. (TM), AstraZeneca ...

AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...

AstraZeneca AZN stock has risen 13.6% in the past six months, outperforming an increase of 7.1% for the industry. AstraZeneca ...